Leukotriene B4 inhibitors: US2009054466; US2009227603 and US2009253684

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 5, 2010, Pages 707-714

  Hutchinson, John H ^a  

^a Amira Pharmaceuticals   (United States)

Author keywords

5 lipoxygenase; Asthma; BLT1R; BLT2R; Cardiovascular disease; Chronic obstructive pulmonary disease; Leukotriene B4

Indexed keywords

2 (2,6 DIHYDROXYHEXYL) 6 (3 HYDROXY 1,5 UNDECADIENYL)PYRIDINE; 5 [2 (2 CARBOXYETHYL) 3 [6 (4 METHOXYPHENYL) 5 HEXENYLOXY]PHENOXY]VALERIC ACID; 5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; US 2009054466; US 2009227603; US 2009253684; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LTB4R PROTEIN, HUMAN; LTB4R2 PROTEIN, HUMAN;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE STRUCTURE; HUMAN; PATENT; REVIEW; ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; INFLAMMATION; PATHOPHYSIOLOGY;

ANIMALS; HUMANS; INFLAMMATION; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE B4; PATENTS AS TOPIC; RECEPTORS, LEUKOTRIENE B4;

EID: 77951596833     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003657180     Document Type: Review

References (50)

1. Samuelsson B. The discovery of the leukotrienes. Am J Respir Crit Care Med 2000;161:s2-6 (Pubitemid 30129406)
2. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B4 receptors. Prostaglandins Leukot Essent Fatty Acids 2003;69:123-134
3. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007;357(18):1841-1854
4. Maekawa A, Kanaoka Y, Xing W, Austen KF. Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci USA 2008;105(43):16695-16700
5. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 2005;337:281-288 (Pubitemid 41393791)
6. Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007;16(12):1909-1920 (Pubitemid 351403723)
7. Okuno T, Iizuka Y, Okazaki H, et al. 12 (S)-hydroxyheptadeca-5Z, 8E, 10Etrienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med 2008;205(4):759-766 (Pubitemid 351549875)
8. Cho K-J, Seo J-M, Shin Y-H, et al. Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low affinity leukotriene B4 receptor. Am J Respir Cell Mol Biol 2009. [Epub ahead of print]
9. Korea University Industrial & Academic Collaboration Foundation. Use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. WO2008117971
10. Kim HJ, Kim DK, Kim H, et al. Involvement of the BLT2 receptor in te itch-associated scratching induced by 12-lipoxygenase products in ICR mice. Br J Pharmacol 2008;154:1073-1078 (Pubitemid 351915073)
11. Xu S, Lu H, Chen Z, Jiang D. Regulation of TNFalpha and IL1beta in rheumatoid arthritis synovial fibroblasts by leukotriene B4. Rheumatol Int Published online 07 October 2009
12. Kim G-Y, Lee J-W, Cho S-H, et al. Role of the low-affinity leukotriene B4 receptor BLT2 in VEGFinduced angiogenesis. Arterioscler Thromb Vasc Biol 2009;29:915-920
13. Korea University Industrial & Academic Collaboration Foundation. Use of inhibitors of leukotriene B4 receptor BLT2 for treating human cancers. WO2008117970
14. Hennig R, Osman T, Esposito I, et al. BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumor cell proliferation. Br J Cancer 2008;99:1064-1073
15. Rocconi RP, Kirby TO, Beck R, et al. Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008;15(3):321-326 (Pubitemid 351550943)
16. Kim EY, Seo JM, Cho KJ, Kim JH. Ras-induced invasion and metastasis are regulated by a leukotriene B(4) receptor BLT2-linked pathway. Oncogene 2009. Published online 23 November 2009
17. Kishikawa K, Tateishi N, Maruyama T, et al. ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins 1992;44:261-275
18. Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B4 receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med 2000;192:421-432 (Pubitemid 30629167)
19. Birke FW, Meade J, Anderskewitz R, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B4 receptor antagonist. J Pharmacol Exp Ther 2001;297:458-466 (Pubitemid 32242607)
20. Diaz-Gonzalez F, Alten RHE, Bensen WG, et al. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:628-632 (Pubitemid 46707131)
21. Diaz-Gonzalez F, Alten RHE, Bensen WG, et al. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:628-632 (Pubitemid 46707131)
22. Konstan MW, Doring G, Lands LC, et al. Results of a phase II clinical trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 2005;s28:125-126
23. Effect of a 14-day treatment with BIIL 284 BS on patients with COPD (doubleblind, placebo-controlled, randomized, parallel study). Royal Brompton & Harefield NHS. Available from: www.rbht.nhs.uk/research/projects/rss/? EntryId31=45041
24. Yokomizo Y, Izumi T, Shimizu T. Leukotriene B4: metabolism and signal transduction. Arch Biochem Biophys 2001;385:231-241
25. Gaber F, James A, Delin I, et al. Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton. J Allergy Clin Immunol 2007;119(5):1267-1268 (Pubitemid 46667158)
26. Hui KP, Taylor IK, Taylor GW, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991;46:184-189
27. Nasser SMS, Bell GS, Hawksworth RJ, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergeninduced early and late asthmatic responses. Thorax 1994;49:743-748
28. McGill KA, Busse WW, Zileuton I. 1996;348:519-524
29. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72-78
30. Yokomiso T, Kato K, Hagiyu H, et al. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem 2001;276(15):12454-12459 (Pubitemid 37385420)
31. Ando K, Tsuji E, Ando Y, et al. Preparation of 2- and 4-(2-alkylcarbamoyl-1-methylvinyl)- 7-alkoxybenzo[b]furans having potent antagonistic activity against human leukotriene B4 BLT1 and/or BLT2 receptors. Org Biomol Chem 2004;2:3427-3431
32. Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev 2005;4:664-672 (Pubitemid 41149760)
33. Helgadottir A, Manolescu A, Helgason A, et al. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006;38:68-74 (Pubitemid 43011884)
34. Back M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009;15(27):3116-3132
35. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120-126 (Pubitemid 34827222)
36. Rossoni G, Sala A, Berti F, et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther 1996;276:335-341 (Pubitemid 26150973)
37. Whatling C, McPheat W, Herslof M. The potential link between athersclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field. Expert Opin Investig Drugs 2007;16:1879-1893 (Pubitemid 351403722)
38. Tardiff J-C, L'Allier PL, Ibrahim R, et al. Three months of treatment with 5-lipoxygenase inhibitor VIA-2291 in patients with recent acute coronary syndrome. Circulation 2008;118(22):2314
39. Via Pharmaceuticals. VIA's lead compound: VIA-2291. Available from: www.viapharmaceuticals.com/via-2291
40. GSK Product Development Pipeline February 2009. Available from: www.gsk.com/investors/product-pipeline/ docs/gsk-pipeline-feb09.pdf
41. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: Finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol 2009;124(3):406-414
42. Lee TH, Woszczek G, Farooque SP. Leukotriene E4: perspective on the forgotten mediator. J Allergy Clin Immunol 2009;124(3):417-421
43. Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 2004;142:861-868 (Pubitemid 39004096)
44. Pfizer, Inc. Pyrazole analogs. WO2008065493
45. Pfizer, Inc. Pyrazole derivatives as 5-LO inhibitors. WO2009069044
46. The effect of MK0633 in patients with chronic asthma. Clinical Trials.gov. Available from: www.clinicaltrials.gov/ ct2/show/NCT00404313? term=MK0633&rank=4205
47. Janssen Pharmaceuticals NV. Arylsubstituted bridged or fused diamines as modulators of leukotriene A4 hydrolase. WO2009058347
48. Janssen Pharmaceuticals NV. Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase. WO2009126806
49. Fourie AM. Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. Curr Opin Investig Drugs 2009;10(11):1173-1182
50. Zileuton to treat adults with chronic obstructive pulmonary disease (the LEUKO Study). ClinicalTrials.gov. Available from: www.clinicaltrial.gov/ct2/ show/NCT00493974